Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $43.9 million.

  • Insight Molecular Diagnostics' Liabilities and Shareholders Equity fell 3742.59% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.9 million, marking a year-over-year decrease of 3469.93%. This contributed to the annual value of $35.1 million for FY2024, which is 5315.79% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Liabilities and Shareholders Equity stood at $43.9 million for Q3 2025, which was down 3742.59% from $50.5 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Liabilities and Shareholders Equity registered a high of $177.4 million during Q2 2021, and its lowest value of $35.1 million during Q4 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' median Liabilities and Shareholders Equity value was $81.6 million (recorded in 2023), while the average stood at $99.3 million.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Liabilities and Shareholders Equity surged by 19136.84% in 2021 and then crashed by 5315.79% in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Liabilities and Shareholders Equity stood at $159.6 million in 2021, then tumbled by 37.27% to $100.1 million in 2022, then decreased by 25.18% to $74.9 million in 2023, then tumbled by 53.16% to $35.1 million in 2024, then grew by 25.24% to $43.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $43.9 million for Q3 2025, versus $50.5 million for Q2 2025 and $60.4 million for Q1 2025.